Chronic Pravastatin but Not Atorvastatin Treatment Impairs Cognitive Function in Two Rodent Models of Learning and Memory

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Stuart, Sarah A ^a   Robertson, James D ^a   Marrion, Neil V ^a   Robinson, Emma S J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PRAVASTATIN; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; LEARNING; LEARNING DISORDER; MALE; MEMORY; MEMORY DISORDER; MENTAL TASK; NONHUMAN; PERCEPTIVE DISCRIMINATION; RAT; TOXICITY TESTING; ANIMAL; BLOOD; BODY WEIGHT; COGNITION; DRUG EFFECTS; PHYSIOLOGY; TIME;

ANIMALS; BODY WEIGHT; CHOLESTEROL; COGNITION; DISCRIMINATION (PSYCHOLOGY); HEPTANOIC ACIDS; MALE; MEMORY; PRAVASTATIN; PYRROLES; RATS; REVERSAL LEARNING; TIME FACTORS;

EID: 84883774071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075467     Document Type: Article

References (61)

1. Hsu I, Spinler SA, Johnson NE, (1995) Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 29: 743-759. PubMed: 8520093.
2. Davidson MH, (2001) Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs 61: 197-206. doi:10.2165/00003495-200161020-00005. PubMed: 11270938.
3. Dales M, (2000) Statination. Intern Med NEWS Vol. 1: 55-56.
4. Dietschy JM, Turley SD, (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12: 105-112. doi:10.1097/00041433-200104000-00003. PubMed: 11264981.
5. Pfrieger FW, (2003) Role of cholesterol in synapse formation and function. Biochim Biophys Acta 1610: 271-280. doi:10.1016/S0005-2736(03)00024-5. PubMed: 12648780.
6. Pfrieger FW, Ungerer N, (2011) Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 50: 357-371. doi:10.1016/j.plipres.2011.06.002. PubMed: 21741992.
7. FDA (2012) Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
8. Etminan M, Gill S, Samii A, (2003) The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 23: 726-730. doi:10.1592/phco.23.6.726.32184. PubMed: 12820814.
9. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA, (2000) Statins and the risk of dementia. Lancet 356: 1627-1631. doi:10.1016/S0140-6736(00)03155-X. PubMed: 11089820.
10. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G, (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443. doi:10.1001/archneur.57.10.1439. PubMed: 11030795.
11. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, et al. (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956-964. doi:10.1212/WNL.0b013e3181d6476a. PubMed: 20200346.
12. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, et al. (2003) Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23: 1663-1667. doi:10.1592/phco.23.15.1663.31953. PubMed: 14695047.
13. Padala KP, Padala PR, Potter JF, (2006) Simvastatin-induced decline in cognition. Ann Pharmacother 40: 1880-1883. doi:10.1345/aph.1H014. PubMed: 16940411.
14. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB, (2004) Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 117: 823-829. doi:10.1016/j.amjmed.2004.07.041. PubMed: 15589485.
15. Evans MA, Golomb BA, (2009) Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 29: 800-811. doi:10.1592/phco.29.7.800. PubMed: 19558254.
16. Abrahamson EE, Ikonomovic MD, Dixon CE, DeKosky ST, (2009) Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol 66: 407-414. doi:10.1002/ana.21731. PubMed: 19798641.
17. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, et al. (2007) Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 206: 59-69. doi:10.1016/j.expneurol.2007.03.031. PubMed: 17521631.
18. Lu D, Qu C, Goussev A, Jiang H, Lu C, et al. (2007) Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 24: 1132-1146. doi:10.1089/neu.2007.0288. PubMed: 17610353.
19. Mans RA, Chowdhury N, Cao D, McMahon LL, Li L, (2010) Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice. Neuroscience 166: 435-444. doi:10.1016/j.neuroscience.2009.12.062. PubMed: 20040368.
20. Wu H, Lu D, Jiang H, Xiong Y, Qu C, et al. (2008) Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 25: 130-139. doi:10.1089/neu.2007.0369. PubMed: 18260796.
21. Baytan SH, Alkanat M, Okuyan M, Ekinci M, Gedikli E, et al. (2008) Simvastatin impairs spatial memory in rats at a specific dose level. Tohoku J Exp Med 214: 341-349. doi:10.1620/tjem.214.341. PubMed: 18441510.
22. Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, et al. (2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59: 1257-1258. doi:10.1212/WNL.59.8.1257. PubMed: 12391360.
23. Oldfield S, Hancock J, Mason A, Hobson SA, Wynick D, et al. (2009) Receptor-mediated suppression of potassium currents requires colocalization within lipid rafts. Mol Pharmacol 76: 1279-1289. doi:10.1124/mol.109.058008. PubMed: 19726551.
24. Vecka M, Tvrzická E, Stanková B, Novák F, Nováková O, et al. (2004) Hypolipidemic drugs can change the composition of rat brain lipids. Tohoku J Exp Med 204: 209-308. doi:10.1620/tjem.204.209. PubMed: 15502420.
25. Lütjohann D, Stroick M, Bertsch T, Kühl S, Lindenthal B, et al. (2004) High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 69: 431-438. doi:10.1016/j.steroids.2004.03.012. PubMed: 15219793.
26. Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, et al. (2006) Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 316: 1146-1152. PubMed: 16282522.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010) Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579. doi:10.1111/j.1476-5381.2010.00872.x. PubMed: 20649561.
28. Javadi-Paydar M, Rayatnia F, Fakhraei N, Zakeri M, Mirazi NA, et al. (2011) Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: involvement of nitric oxide. Brain Res 1386: 89-99. doi:10.1016/j.brainres.2011.02.057. PubMed: 21354117.
29. Douma TN, Borre Y, Hendriksen H, Olivier B, Oosting RS, (2011) Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berl) 216: 537-544. doi:10.1007/s00213-011-2245-0.
30. Shepherd SJ, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG, (2003) Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 91(5A):: 11C-17C. PubMed: 12646338.
31. Zhou Z, Rahme E, Pilote L, (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J, 151: 273-281. doi:10.1016/j.ahj.2005.04.003. PubMed: 16442888.
32. Birrell JM, Brown VJ, (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320-4324. PubMed: 10818167.
33. Idris NF, Repeto P, Neill JC, Large CH, (2005) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 179: 336-348. doi:10.1007/s00213-004-2058-5. PubMed: 15645224.
34. Jentsch JD, Taylor JR, (2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 24: 66-74. doi:10.1016/S0893-133X(00)00174-3. PubMed: 11106877.
35. Jones GH, Marsden CA, Robbins TW, (1991) Behavioural rigidity and rule-learning deficits following isolation-rearing in the rat: neurochemical correlates. Behav Brain Res 43: 35-50. doi:10.1016/S0166-4328(05)80050-6. PubMed: 1677579.
36. Robbins TW, (2002) The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 163: 362-380. doi:10.1007/s00213-002-1154-7. PubMed: 12373437.
37. Mackintosh N, Little L, (1969) Selective attention and response strategies as factors in serial reversal learning. Can J Psychol 23: 335-346. doi:10.1037/h0082821.
38. Aggleton JP, Hunt PR, Rawlins JN, (1986) The effects of hippocampal lesions upon spatial and non-spatial tests of working memory. Behav Brain Res 19: 133-146. doi:10.1016/0166-4328(86)90011-2. PubMed: 3964405.
39. Ennaceur A, Delacour J, (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31: 47-59. doi:10.1016/0166-4328(88)90157-X. PubMed: 3228475.
40. Barker GR, Bird F, Alexander V, Warburton EC, (2007) Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 27: 2948-2957. doi:10.1523/JNEUROSCI.5289-06.2007. PubMed: 17360918.
41. Mumby DG, Piterkin P, Lecluse V, Lehmann H, (2007) Perirhinal cortex damage and anterograde object-recognition in rats after long retention intervals. Behav Brain Res 185: 82-87. doi:10.1016/j.bbr.2007.07.026. PubMed: 17804090.
42. Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ, (2004) Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci 24: 5901-5908. doi:10.1523/JNEUROSCI.1346-04.2004. PubMed: 15229237.
43. Warburton EC, Koder T, Cho K, Massey PV, Duguid G, et al. (2003) Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. Neuron 38: 987-996. doi:10.1016/S0896-6273(03)00358-1. PubMed: 12818183.
44. Tinsley CJ, Narduzzo KE, Brown MW, Warburton EC, (2012) A role for the CAMKK pathway in visual object recognition memory. Hippocampus 22: 466-476. doi:10.1002/hipo.20913. PubMed: 21298728.
45. McTavish D, Sorkin EM, (1991) Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42: 65-89. doi:10.2165/00003495-199142010-00005. PubMed: 1718686.
46. Botti RE, Triscari J, Pan HY, Zayat J, (1991) Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14: 256-261. doi:10.1097/00002826-199106000-00010. PubMed: 1906375.
47. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, et al. (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312: 786-793. PubMed: 15358814.
48. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, et al. (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274: 13675-13680. doi:10.1074/jbc.274.19.13675. PubMed: 10224140.
49. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, et al. (2004) Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol 483: 133-138. doi:10.1016/j.ejphar.2003.10.017. PubMed: 14729100.
50. Tsuji A, Saheki A, Tamai I, Terasaki T, (1993) Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 267: 1085-1090. PubMed: 8263769.
51. Jones P, Kafonek S, Laurora I, Hunninghake D, (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587. doi:10.1016/S0002-9149(97)00965-X. PubMed: 9514454.
52. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630. doi:10.1016/S0140-6736(02)11600-X. PubMed: 12457784.
53. Takemoto M, Liao JK, (2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719. doi:10.1161/hq1101.098486. PubMed: 11701455.
54. Van Aelst L, D'Souza-Schorey C, (1997) Rho GTPases and signaling networks. Genes Dev 11: 2295-2322. doi:10.1101/gad.11.18.2295. PubMed: 9308960.
55. Brambilla R, Gnesutta N, Minichiello L, White G, Roylance AJ, et al. (1997) A role for the Ras signalling pathway in synaptic transmission and long-term memory. Nature 390: 281-286. doi:10.1038/36849. PubMed: 9384379.
56. Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, et al. (2006) Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 36: 2885-2893. doi:10.1002/eji.200636567. PubMed: 17048274.
57. Hering H, Lin CC, Sheng M, (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23: 3262-3271. PubMed: 12716933.
58. Schachter M, (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19: 117-125. PubMed: 15660968.
59. Rosenson RS, (2003) Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 1: 495-505. doi:10.1586/14779072.1.4.495. PubMed: 15030249.
60. McTaggart F, Buckett L, Davidson R, (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxyl-3methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87: 28-32. doi:10.1016/S0002-9149(01)01719-2. PubMed: 11137829.
61. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB, (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study J. Neurol Neurosurg Psychiatry 80: 13-17. doi:10.1136/jnnp.2008.150433.